Galderma Group AG (SWX:GALD)

Switzerland · Delayed Price · Currency is CHF

127.50

-2.50 (-1.92%)

Jul 31, 2025, 5:31 PM CET

-1.92% (1Y)

Market Cap	30.27B
Revenue (ttm)	3.73B
Net Income (ttm)	300.62M
Shares Out	237.41M
EPS (ttm)	1.26
PE Ratio	100.86
Forward PE	45.59
Dividend	0.15 (0.12%)
Ex-Dividend Date	Apr 25, 2025

Volume	1,265,917
Average Volume	1,315,738
Open	130.90
Previous Close	130.00
Day's Range	126.80 - 131.70
52-Week Range	66.43 - 138.80
Beta	n/a
RSI	56.24
Earnings Date	Jul 24, 2025

About Heartland Financial USA

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Actinica, Dysport/Azzalure, Alluzience, Restylane and Restylane Skinboosters, Sculptra, Cetaphil and Alastin, Soolantra, Epiduo and Epiduo Forte, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Mirvaso, Nemluvio, Relfydess, Benzac, Loceryl, and TRI-LUMA in ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1981

Employees 6,545

Stock Exchange SIX Swiss Exchange

Ticker Symbol GALD

Full Company Profile

Financial Performance

Financial Statements

News

Galderma Announces Departure of Its Chief Financial Officer

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland — Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, wi...

4 weeks ago - Financial Post

Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba

ZUG, Switzerland — Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild ...

2 months ago - Financial Post